title: AML in 2016: Where we are now?
abstract: A high relapse rate for patients with acute myeloid leukemia (AML) is still a major barrier to the long-term survival of these patients. Nevertheless, considerable progress has been made both in the biology and therapy of the disease. Specifically, progress has been made in the areas of integrated genomic analysis for prognosis, the widening application of minimal residual disease (MRD) monitoring in clinical practice, the development of new agents, and the increasing use of drugs, such as IDH and FLT3 inhibitors, as a bridge to transplant. Continued progress and inquiry into these and other areas are essential to improve the survival outcome for adult patients with AML.
authors.affiliation: Technion Israel Institute of Technology, Haifa, Israel; Department of Hematology, Rambam Health Care Campus, Haifa, Israel; Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel. Electronic address: rowe@rambam.health.gov.il.
authors.forename: Jacob M
authors.initials: JM
authors.lastname: Rowe
mesh_terms: D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000188:drug therapy / Q000201:enzymology / Q000401:mortality; D018365:Neoplasm, Residual; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D051941:fms-Like Tyrosine Kinase 3 / Q000037:antagonists & inhibitors
chemical_list: D047428:Protein Kinase Inhibitors; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3
keywords: ALL; AML; Acute leukemia forum; Acute lymphoblastic leukemia; Acute myeloid leukemia; Blinatumomab; Genomics; IDH; MRD; Minimal residual disease